ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?

Zacks2024-12-11

ADMA Biologics ADMA is witnessing a phenomenal run this year. Its shares have skyrocketed 320.6% year to date against the industry’s decline of 7.4%. The stock has also outperformed the sector and the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490023572?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/r3LkX1bo0SJtXvRIU47BTQ--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3615a98c17145f2f704cb1a2bf1cf669","is_english":true,"pubTime":"2024-12-11 02:13","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490023572","market":"us","top_or_hot":-1,"title":"ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?","media":"Zacks","content":"<div>\n<p>ADMA Biologics ADMA is witnessing a phenomenal run this year. Its shares have skyrocketed 320.6% year to date against the industry’s decline of 7.4%. The stock has also outperformed the sector and the...</p>\n\n<a href=\"https://finance.yahoo.com/news/adma-stock-falls-19-52-181300731.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 02:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/adma-stock-falls-19-52-181300731.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ADMA Biologics ADMA is witnessing a phenomenal run this year. Its shares have skyrocketed 320.6% year to date against the industry’s decline of 7.4%. The stock has also outperformed the sector and the...</p>\n\n<a href=\"https://finance.yahoo.com/news/adma-stock-falls-19-52-181300731.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRFS","symbol_name":"基立福","start_time":0,"source_url":"https://finance.yahoo.com/news/adma-stock-falls-19-52-181300731.html","article_id":"2490023572","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/r3LkX1bo0SJtXvRIU47BTQ--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3615a98c17145f2f704cb1a2bf1cf669"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490023572","pubTimestamp":1733854380,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"ADMA Biologics ADMA is witnessing a phenomenal run this year. Its shares have skyrocketed 320.6% year to date against the industry’s decline of 7.4%. The stock has also outperformed the sector and the S&P 500 during the aforementioned period.ADMA has recently hit a new 52-week high of $23.64 on Nov. 11. The stock fell 19% since then and is currently trading at $19.01.The stupendous rally can be attributed to the company’s consistently strong quarterly performance and increased guidance.ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.The company’s top line currently comprises sales of three FDA-approved products — Bivigam , Asceniv  and Nabi-HB .ADMA expects to file its supplemental biologics license application  over the coming quarters, with a potential approval for label expansion in the first half of 2026. A potential label expansion will strengthen ADMA’s product portfolio.While reporting thi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRFS":"基立福","ADMA":"ADMA Biologics Inc","BK4139":"生物科技","TAK":"武田制药","BK4007":"制药"},"translate_title":"ADMA股价较52周高点下跌19%：您应该逢低买入吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1,"GRFS":1,"TAK":1},"content_text":"ADMA Biologics ADMA is witnessing a phenomenal run this year. Its shares have skyrocketed 320.6% year to date against the industry’s decline of 7.4%. The stock has also outperformed the sector and the S&P 500 during the aforementioned period.\nADMA has recently hit a new 52-week high of $23.64 on Nov. 11. The stock fell 19% since then and is currently trading at $19.01.\nThe stupendous rally can be attributed to the company’s consistently strong quarterly performance and increased guidance.\nADMA Outperforms Industry, Sector & S&P 500\nImage Source: Zacks Investment Research\nAsceniv’s Performance Fuels ADMA’s Growth\nADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.\nThe company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).\nAsceniv is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body’s immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease. Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company’s proprietary microneutralization assay.\nTotal revenues in the third quarter jumped 78% due to increased sales of Asceniv and third-party plasma sales by ADMA’s BioCenters business segment.\nADMA’s Efforts to Expand Asceniv’s Label\nIn connection with the FDA’s approval of Asceniv in April 2019, ADMA is required to conduct a pediatric study to evaluate the safety and efficacy of Asceniv in children and adolescents. The ongoing post-marketing study for Asceniv may provide a label expansion opportunity to include pediatric-aged PI patients.\nAll pediatric patients in Asceniv’s post-marketing pediatric study have now successfully completed their treatment schedule, and the clinical trial database is on track to be locked in the fourth quarter of 2024.\nADMA expects to file its supplemental biologics license application (sBLA) over the coming quarters, with a potential approval for label expansion in the first half of 2026. A potential label expansion will strengthen ADMA’s product portfolio.\nADMA’s Financial Targets\nWhile reporting third-quarter results, ADMA raised its outlook for 2024 and 2025 yet again. ADMA now expects to generate revenues of more than $415 million in 2024 and $465 million in 2025 (previous guidance: more than $400 million in 2024 and $445 million in 2025). Net income is projected to exceed $120 million in 2024 and $165 million in 2025 (up from the prior guidance of $105 million for 2024 and $155 million for 2025).\nMargin Improvement\nADMA’s higher-margin product portfolio now accounts for more than 50% of its total revenues. The company is working to increase Asceniv's supply. If successful, Asceniv will account for a significant portion of ADMA's total revenues over time, further advancing its potential margin expansion and earnings growth.\nValuation & Estimates\nGoing by the price/sales ratio, ADMA’s shares currently trade at 9.19x forward sales, higher than its mean of 3.46x and the industry’s 1.72x.\nImage Source: Zacks Investment Research\nThe bottom-line estimate for 2024 earnings per share has increased 3 cents to 52 cents over the past 60 days, and the same for 2025 has jumped 14 cents.\nImage Source: Zacks Investment Research\nConclusion\nADMA Biologics, which competes with Takeda TAK and Grifols GRFS in the U.S. market for plasma-derived products, is poised to perform well in the upcoming quarters. Incremental additional penetration of Asceniv should accelerate near-term revenue growth.\nThe targeted market has significant potential. Management expects additional opportunities for ADMA to continue to grow substantially in the underserved, immune-compromised and co-morbid patient population despite the availability of standard-of-care therapy.\nLarge biotech companies are generally considered safe havens for investors interested in this sector. Despite the exceptional rally this year, the stock will likely grow further, given the investors’ confidence in its prospects. Hence, any dip can be used as a buying opportunity.\nFor investors already owning the stock, staying invested would be a prudent move.\nADMA currently carries a Zacks Rank #2 (Buy).  You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nGrifols, S.A. (GRFS) : Free Stock Analysis Report\nADMA Biologics Inc (ADMA) : Free Stock Analysis Report\nTakeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490023572"}